Examkin

Question

Difficulty: Very hardMonitoring and Treatment Evaluation

A 45-year-old woman is evaluated in the transplant clinic 3 months after receiving a deceased-donor renal allograft. Her maintenance immunosuppression regimen includes tacrolimus, mycophenolate mofetil, and prednisone. Routine surveillance laboratory testing reveals a new quantitative cytomegalovirus (CMV) DNA viral load of 15,000 IU/mL15,000 \text{ IU/mL}. She is currently asymptomatic and her renal allograft function is stable. The decision is made to manage this active CMV infection to prevent progression to tissue-invasive disease.

Arrange the following steps in the correct chronological sequence for the therapeutic management, monitoring, and evaluation of this patient's CMV infection.

  1. 1Initiate induction-dose antiviral therapy with oral valganciclovir.
  2. 2Perform weekly surveillance of quantitative CMV DNA viral load and complete blood counts.
  3. 3Order genotypic resistance testing for viral mutations if the viral load fails to decline after two weeks.
  4. 4Transition the antiviral regimen to oral maribavir or intravenous foscarnet if clinically significant resistance is confirmed.
  5. 5Maintain the effective antiviral regimen until consecutive assays demonstrate an undetectable viral load.

Answer

The correct sequence begins with initiating oral valganciclovir, followed by weekly monitoring of the viral load and CBC. If the viral load does not decline after 14 days, genotypic resistance testing is ordered. If resistance is confirmed, therapy is switched to maribavir or foscarnet. Finally, the effective therapy is continued until the virus is undetectable.
The standard algorithm for monitoring and evaluating CMV treatment in a transplant recipient begins with initiating first-line therapy (valganciclovir). Efficacy and toxicity are monitored via weekly viral loads and complete blood counts. If the viral load is refractory after a sufficient therapeutic trial (at least 2 weeks), genotypic testing is indicated to look for UL97 or UL54 mutations. If resistance is confirmed, switching to maribavir or foscarnet is the standard next step. Regardless of whether the patient responds to the first or second-line agent, induction therapy must be continued until the viral load is proven undetectable on consecutive weekly tests.

Step-by-Step Solution

1
Initiate induction-dose antiviral therapy with oral valganciclovir.
The patient begins standard first-line therapy for active CMV infection.
Oral valganciclovir is highly bioavailable and equivalent to intravenous ganciclovir for asymptomatic CMV viremia in solid organ transplant recipients.
2
Perform weekly surveillance of quantitative CMV DNA viral load and complete blood counts.
Treatment response and potential drug-induced toxicities are systematically monitored.
Weekly viral loads objectively assess the efficacy of treatment. CBC monitoring is essential due to the high risk of valganciclovir-induced myelosuppression.
3
Order genotypic resistance testing for viral mutations if the viral load fails to decline after two weeks.
Refractory CMV infection is identified and formally evaluated for antiviral resistance.
A lack of virologic response after 14 days of properly dosed therapy raises the suspicion for resistance mutations, necessitating genotypic analysis before arbitrarily changing medications.
4
Transition the antiviral regimen to oral maribavir or intravenous foscarnet if clinically significant resistance is confirmed.
The patient is placed on an effective second-line therapy.
Maribavir and foscarnet are effective for ganciclovir-resistant CMV isolates because their mechanisms of action bypass the viral UL97 kinase mutation.
5
Maintain the effective antiviral regimen until consecutive assays demonstrate an undetectable viral load.
The active CMV infection is successfully cleared.
Induction therapy duration is strictly guided by virologic endpoints, requiring consecutive weekly negative assays to confirm clearance before stopping treatment or transitioning to secondary prophylaxis.

Key Concept

The chronological management of CMV viremia in solid organ transplant recipients requires initiating valganciclovir, weekly virologic monitoring, resistance testing if treatment fails at two weeks, appropriate therapy transition for confirmed resistance, and continuation of treatment until complete virologic clearance.
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic